An Approach to Developing Novel Clinical Outcome Assessments: 
A Rare Disease Webinar with CDER ARC's LEADER 3D Program

December 11, 2026
12-2pm (eastern)

About the Webinar

Clinical Outcome Assessments (COAs) are measures that describe or reflect how a patient feels or functions. An Approach to Developing Novel Clinical Outcome Assessments webinar will explore important considerations for the development of novel COAs in rare disease drug development programs. The webinar also will highlight how patient experience data can be leveraged to develop both meaningful and measurable COAs. The case study, odevixibat (Bylvay), a drug approved by the FDA in 2021 for the treatment of pruritus in progressive familial intrahepatic cholestasis (PFIC), will exemplify these important issues. 
This webinar, convened in collaboration with FDA’s Center for Drug Evaluation and Research Center’s (CDER) Accelerating Rare Disease Cures (ARC)  LEADER 3D Program, is designed to further drug developers’ understanding of the regulatory pathways, illuminate successful sponsor/FDA CDER interactions, and offer resources to increase the efficiency of rare disease drug development. ​

Agenda Topics

  • Introduction to LEADER 3D and the Case Study 
  • Case Study Presentation: Odevixibat (Bylvay)
  • Selecting and Developing Fit-for-Purpose Clinical Outcome Assessments (COAs)
  • Patient-Focused Drug Development (PFDD): Enhancing the Incorporation of the Patient’s Voice

About LEADER 3D

Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D) is a program of FDA’s Center for Drug Evaluation and Research Center’s (CDER) Accelerating Rare Disease Cures (ARC) program. 

​CDER recognizes that aspects of drug development that are feasible for common diseases may not be feasible for rare diseases and that development challenges are often greater with the increasing rarity of the disease. CDER ARC’s LEADER 3D initiative aims to better understand and address the unique challenges in bringing rare disease products  regulated by CDER to market, such as small patient populations, disease heterogeneity, and novel endpoint development and selection. 

This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an award of $ 86,689 in federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit FDA.gov.